LSE:ARIX

Scheme Effective

Retrieved on: 
Monday, February 12, 2024
RTW, Letter, Regulation, Financial services, Person, Sale, Prejudice, Regulation D, Risk, International (Amtrak train), Jefferies

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Suspension of Trading in Shares

Retrieved on: 
Monday, February 12, 2024
RTW, Letter, Regulation, Financial services, Person, Sale, Prejudice, Regulation D, Risk, International (Amtrak train), Jefferies

The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.

Key Points: 
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
  • The transferability of the Consideration Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any Consideration Shares in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Transaction Update

Retrieved on: 
Wednesday, February 7, 2024
RTW, Regulation D, Financial services, CREST, Calendar, Prejudice, International (Amtrak train), Person, Jefferies, Regulation, Second, Risk, Letter, Sale, Form, Security (finance)

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Unaudited NAV for December 2023

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology

LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows:

Key Points: 
  • LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows:

Update on the Scheme and Publication of Notice of Second General Meeting

Retrieved on: 
Tuesday, January 30, 2024
Jefferies, International (Amtrak train), Financial services, Person, Letter, Prejudice, Form, Risk, Regulation D, Sale, RTW, Second, Regulation, CREST, Calendar, Security (finance)

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.
  • If the Second General Meeting is adjourned, the Voting Record Time for the adjourned meeting will be 6.30 p.m. on the date two calendar days before the date set for the adjourned meeting.

Financial update on Harpoon Therapeutics acquisition by Merck (MSD)

Retrieved on: 
Tuesday, January 30, 2024
MSD, Patient, Therapy, Biotechnology, Cancer, Sale, Acquisition, MRK, Pharmaceutical industry

LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.

Key Points: 
  • LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
  • The sale of Harpoon is expected to deliver net proceeds to Arix of approximately $18.9 million (£14.9 million [1]).
  • This acquisition by Merck provides significant potential for bringing life-saving treatment to cancer patients as they enhance their oncology pipeline.
  • [1] At prevailing GBP/USD FX rate on 18 January 2024.

Holding(s) in Company

Retrieved on: 
Tuesday, January 30, 2024
Security (finance)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Key Points: 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
5. Date on which the threshold was crossed or reached vi:
% of voting rights attached to shares (total of 8. A)

Results of First General Meeting

Retrieved on: 
Tuesday, January 30, 2024
Jefferies, International (Amtrak train), Financial services, Person, Letter, Prejudice, Risk, Regulation D, Sale, RTW, Regulation

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Update on the Scheme and Resignation of Directors

Retrieved on: 
Tuesday, January 30, 2024
Jefferies, International (Amtrak train), Financial services, GBP, Person, Letter, Prejudice, Risk, Regulation D, Sale, RTW, Regulation

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.